Fresenius Kidney Care-Pleasant View is a medicare approved dialysis facility center in Farr West, Utah and it has 12 dialysis stations. It is located in Weber county at 1735 W 2700 N, Farr West, UT, 84414. You can reach out to the office of Fresenius Kidney Care-Pleasant View at (801) 737-9664. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fresenius Kidney Care-Pleasant View has the following ownership type - Profit. It was first certified by medicare in October, 2017. The medicare id for this facility is 462550 and it accepts patients under medicare ESRD program.
| Name | Fresenius Kidney Care-Pleasant View |
|---|---|
| Location | 1735 W 2700 N, Farr West, Utah |
| No. of Dialysis Stations | 12 |
| Medicare ID | 462550 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 1735 W 2700 N, Farr West, Utah, 84414 | |
| (801) 737-9664 | |
| Not Available |
News Archive
Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the National Cancer Institute, a division of the U.S. National Institutes of Health (NIH), has selected its proprietary Tunable Green Fiber Laser (TGFL) for research in flow cytometry.
Neogenix Oncology, Inc. has announced that the company's novel antibody NEO-101, which targets pancreatic and colorectal cancer cells, has been selected as one of Windhover's 2011 Top 10 Projects to Watch.
Weightlifters could do less and get stronger by changing the amount they lift each session, according to new research.
Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.
Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients.
› Verified 3 days ago
| NPI Number | 1407394463 |
| Doing Business As | Fresenius Medical Care Pleasant View, Llc |
| Address | 1735 West 2700 North Farr West, Utah, 84404 |
| Phone Number | (801) 737-9664 |
News Archive
Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the National Cancer Institute, a division of the U.S. National Institutes of Health (NIH), has selected its proprietary Tunable Green Fiber Laser (TGFL) for research in flow cytometry.
Neogenix Oncology, Inc. has announced that the company's novel antibody NEO-101, which targets pancreatic and colorectal cancer cells, has been selected as one of Windhover's 2011 Top 10 Projects to Watch.
Weightlifters could do less and get stronger by changing the amount they lift each session, according to new research.
Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.
Bcl-2-like protein 11 (BIM) deletion in advanced non-small cell lung cancer (NSCLC) is associated with shorter progression free survival (PFS) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or chemotherapy treated Asian patients.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.